DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for Pituitary Gland Adenoma — screening already-approved drugs against its 14-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePituitary Gland Adenoma maps to a 14-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pituitary gland adenoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
dopamine receptor D2 (DRD2) — DRD2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 8alphadrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9BS9 · 2.28 Å · ligand (8alpha)-N,N-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide (7LD). Experimental structure, not a prediction.
What the evidence adds up to
A 2022 review of molecular biology in pituitary adenomas reports that these tumours are increasing in both incidence and prevalence and that crucial knowledge gaps remain in understanding the underlying molecular pathways that distinguish tumour from normal gland. The review, based on a PubMed search covering secretory subtypes and transcription factors, states that understanding these pathways is a fundamental step toward guiding future treatment but does not report any specific drug, survival data, or response rates.
A 2011 article discusses attempts to develop markers that correlate with tumour behaviour, specifically to identify lesions with increased potential for malignancy, metastasis, invasion, or recurrence after treatment. The article addresses the role of surgery in aggressive or invasive pituitary adenomas but provides no drug names, no survival figures, and no response rates.
A 2012 review of medical treatment for clinically nonfunctioning pituitary adenomas notes that these are the most common subtype, often diagnosed late because they cause no detectable hormonal hypersecretion. The tumours are benign but frequently invade surrounding tissues, making complete surgical removal difficult, and relapse is common. The review states that new medications have shown certain effectiveness in reducing tumour size and improving clinical symptoms, but it gives no drug names, no concrete numbers for tumour shrinkage, and no survival or response data.
What is still missing are large, prospective clinical trials that test specific drugs against placebo or standard care in defined patient subgroups, adequate funding for such trials, and validated biomarkers that can stratify patients by likely response. No drug has been shown in these abstracts to improve survival or produce a reliable objective response rate in pituitary adenoma.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Recent advancements in the molecular biology of pituitary adenomas
AbstractINTRODUCTION: Pituitary adenomas are a common and diverse group of intracranial tumors arising from the anterior pituitary that are usually slow-growing and benign, but still pose a significant healthcare burden to patients. Additionally, they are increasing in both incidence and prevalence, leading to a need for better understanding of molecular changes in the development of these tumors. AREAS COVERED: A PubMed literature search was conducted using the terms 'pituitary adenoma' in combination with keywords related to secretory subtype: lactotroph, somatotroph, corticotroph, gonadotroph and null cell, in addition to their transcription factor expression: PIT1, TPIT, and SF-1. Articles resulting from this search were analyzed, as well as relevant articles cited as their references. In this review, we highlight recent advances in the genetic and epigenetic characterization of individual pituitary adenoma subtypes and the effect it may have on guiding future clinical treatment of these tumors. EXPERT OPINION: Understanding the molecular biology of pituitary adenomas is a fundamental step toward advancing the treatment of these tumors. Yet crucial knowledge gaps exist in our understanding of the underlying molecular biology of pituitary adenomas which can potentially be addressed by turning to differentially activated molecular pathways in tumor relative to normal gland.
Recent Advances in Diagnosis and Treatment of Aggressive Pituitary Tumors and Pituitary Carcinomas
AbstractOver the past few decades, attempts have been made to develop markers that correlate with the behavior of pituitary adenomas to identify lesions with an increased potential for malignancy (metastasis, invasion, or recurrence following treatment) [Zada G et al. J Neurosurg 2011]. This article discusses the role of surgery in the treatment of agressive/invasive pituitary adenomas.
Advances in medical treatment of clinically nonfunctioning pituitary adenomas.
AbstractClinically nonfunctioning pituitary adenomas are the most common types among pituitary adenomas. These tumors are usually diagnosed in their later stages due to the absence of clinical symptoms and detectable hormonal hypersecretion. Although these tumors are benign, they are hard to be completely removed during neurosurgery due to the massive invasion into the surrounding tissues at diagnosis. Furthermore, relapse is common. In recent years, medical treatment of pituitary adenomas has witnessed a rapid development. New medications have shown certain effectiveness in reducing the tumor size and improving the clinical symptoms.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
